DE69631835D1 - Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten - Google Patents

Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Info

Publication number
DE69631835D1
DE69631835D1 DE69631835T DE69631835T DE69631835D1 DE 69631835 D1 DE69631835 D1 DE 69631835D1 DE 69631835 T DE69631835 T DE 69631835T DE 69631835 T DE69631835 T DE 69631835T DE 69631835 D1 DE69631835 D1 DE 69631835D1
Authority
DE
Germany
Prior art keywords
multivalent
ultrafiltration
proteasomen
sub
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631835T
Other languages
English (en)
Other versions
DE69631835T3 (de
DE69631835T2 (de
Inventor
H Lowell
D Zollinger
F Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Quebec
US Army Medical Research and Materiel Command USAMRMC
Original Assignee
ID Biomedical Corp of Quebec
US Army Medical Research and Materiel Command USAMRMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69631835(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ID Biomedical Corp of Quebec, US Army Medical Research and Materiel Command USAMRMC filed Critical ID Biomedical Corp of Quebec
Application granted granted Critical
Publication of DE69631835D1 publication Critical patent/DE69631835D1/de
Publication of DE69631835T2 publication Critical patent/DE69631835T2/de
Publication of DE69631835T3 publication Critical patent/DE69631835T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1275Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE69631835T 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten Expired - Lifetime DE69631835T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
US003859P 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (3)

Publication Number Publication Date
DE69631835D1 true DE69631835D1 (de) 2004-04-15
DE69631835T2 DE69631835T2 (de) 2005-02-10
DE69631835T3 DE69631835T3 (de) 2009-03-05

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631835T Expired - Lifetime DE69631835T3 (de) 1995-09-18 1996-09-18 Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten

Country Status (20)

Country Link
US (1) US6476201B1 (de)
EP (1) EP0854729B2 (de)
JP (2) JP4033489B2 (de)
KR (1) KR19990045763A (de)
CN (1) CN1211192A (de)
AT (1) ATE261313T1 (de)
BR (1) BR9610484A (de)
CA (1) CA2232410C (de)
CZ (1) CZ298460B6 (de)
DE (1) DE69631835T3 (de)
DK (1) DK0854729T3 (de)
EA (1) EA199800208A1 (de)
ES (1) ES2217325T5 (de)
HU (1) HUP9901577A3 (de)
IL (1) IL123720A (de)
MX (1) MX9802128A (de)
NO (1) NO320074B1 (de)
PL (1) PL325604A1 (de)
PT (1) PT854729E (de)
WO (1) WO1997010844A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1228217B1 (de) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Konservierte antigene aus neisseria
MXPA01011867A (es) 1999-05-19 2002-05-06 Chiron Spa Composiciones neisseriales de combinacion.
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
EP1721618A3 (de) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteasom-influenzavirus-impfstoffzusammensetzung
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
EP2255826B1 (de) * 2002-08-02 2016-04-13 GlaxoSmithKline Biologicals S.A. Neisseria impfstoffzusammensetzungen die eine kombination von antigenen enthalten
PT2353608T (pt) * 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
WO2005027964A1 (en) * 2003-09-15 2005-03-31 Id Biomedical Corporation Of Quebec Measles subunit vaccine
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
SG186686A1 (en) 2004-06-25 2013-01-30 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
EP1778283A2 (de) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccinzusammensetzungen zur behandlung von coronavirusinfektion
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
TWI565713B (zh) 2006-08-07 2017-01-11 哈佛大學校長及研究員協會 蛋白基質疫苗以及該疫苗的製造與使用方法
US20100288029A1 (en) * 2006-08-30 2010-11-18 Ge Healthcar Bio-Sciences Corp. System and method for characterizing membranes and membrane filtration devices
JP5723768B2 (ja) * 2008-05-30 2015-05-27 ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー, オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ 髄膜炎菌性多価未変性外膜小胞ワクチン、その作製方法およびその使用
AU2010292195A1 (en) * 2009-09-09 2012-03-15 Matrivax Research & Development Corp. Protein matrix vaccines of improved immunogenicity
AU2015321698B2 (en) * 2014-09-24 2018-06-28 The United States Of America As Represented By The Secretary Of The Navy Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (ru) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Способ получения инактивированной вакцины гриппа
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
WO1994002626A1 (en) * 1992-07-20 1994-02-03 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung

Also Published As

Publication number Publication date
CA2232410C (en) 2003-06-17
PL325604A1 (en) 1998-08-03
MX9802128A (es) 1998-11-29
BR9610484A (pt) 2001-09-11
US6476201B1 (en) 2002-11-05
EP0854729B1 (de) 2004-03-10
NO981189L (no) 1998-05-14
NO320074B1 (no) 2005-10-17
DE69631835T3 (de) 2009-03-05
IL123720A (en) 2002-02-10
CZ81998A3 (cs) 1998-10-14
CN1211192A (zh) 1999-03-17
EA199800208A1 (ru) 1998-10-29
NO981189D0 (no) 1998-03-17
PT854729E (pt) 2004-08-31
HUP9901577A2 (hu) 1999-08-30
JP2004099619A (ja) 2004-04-02
EP0854729A1 (de) 1998-07-29
EP0854729B2 (de) 2008-10-22
CA2232410A1 (en) 1997-03-27
JP2000507913A (ja) 2000-06-27
ES2217325T5 (es) 2009-04-01
DE69631835T2 (de) 2005-02-10
DK0854729T3 (da) 2004-07-12
KR19990045763A (ko) 1999-06-25
JP4033489B2 (ja) 2008-01-16
WO1997010844A1 (en) 1997-03-27
CZ298460B6 (cs) 2007-10-10
ES2217325T3 (es) 2004-11-01
EP0854729A4 (de) 2000-02-02
HUP9901577A3 (en) 2000-03-28
ATE261313T1 (de) 2004-03-15
US20020164357A1 (en) 2002-11-07
IL123720A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
DE69631835D1 (de) Verbesserte verfahren zur herstellung von nichtkovalent komplexierten und multivalenten impfstoffen gegen proteasomen-untereinheiten
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
EP1297844A3 (de) Meningokokkus Multikomponentimpfstoff
GR3033469T3 (en) Preparation and uses of LOS-depleted outer membrane proteins of gram-negative cocci.
DE69110663D1 (de) Verfahren zur herstellung eines enzymhydrolysates.
SE9003278D0 (sv) Foerfarande respektive anlaeggning foer beredning av en medicinsk loesning, t ex en dialysloesning
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
Amend et al. Some factors affecting the potency of Yersinia ruckeri bacterins
DE59107901D1 (de) Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren
DE69104365D1 (de) Vaterit und verfahren zu dessen herstellung.
JP2002537352A (ja) ナイセリアワクチン組成物および方法
PT90310B (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
DE69713089D1 (de) Verfahren zur herstellung von immunoaktiven mittel und impfstoffe
EP0082072B1 (de) Verfahren zur Herstellung eines biochemischen Vakzins gegen Salmonellenfieber
CH662056A5 (fr) Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies.
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
IT1206250B (it) Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
DE69804850D1 (de) Verfahren zur herstellung eines kappa-casein-glykomakropeptides oder eines abkoemmlings davon
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
ATE266676T1 (de) Verwendung von aviären, vitellinen, gegen hiv- antigene gerichteten antikörpern zur herstellung pharmazeutischer zubereitungen
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
SU1725904A1 (ru) Способ получени бруцеллезной вакцины из штамма 82
RU93052669A (ru) Способ получения специфического лактоглобулина
RU97115149A (ru) Способ вакцинации против вирусного гепатита в
Lee " Rocks, Orchids, and Bamboo" by Shih-t'ao

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: KRAMER - BARSKE - SCHMIDTCHEN, 81245 MUENCHEN

8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings